SAB Biotherapeutics, Inc., (SABS): Price and Financial Metrics
SABS Price/Volume Stats
| Current price | $1.76 | 52-week high | $5.01 |
| Prev. close | $1.79 | 52-week low | $1.00 |
| Day low | $1.72 | Volume | 8,600 |
| Day high | $1.82 | Avg. volume | 80,563 |
| 50-day MA | $1.71 | Dividend yield | N/A |
| 200-day MA | $2.47 | Market Cap | 16.35M |
SABS Stock Price Chart Interactive Chart >
SAB Biotherapeutics, Inc., (SABS) Company Bio
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases, such as COVID-19 and influenza, immune system disorders comprising type 1 diabetes, organ transplantation, and cancer. The company was founded in 2014 and is based in Miami Beach, Florida.
SABS Price Returns
| 1-mo | -2.76% |
| 3-mo | 15.03% |
| 6-mo | -57.89% |
| 1-year | -40.54% |
| 3-year | -88.27% |
| 5-year | N/A |
| YTD | -53.61% |
| 2024 | -44.81% |
| 2023 | 16.55% |
| 2022 | -92.45% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...